Ningbo Menovo Pharm Co Ltd Market Cap ($1.01 Billion)
Market Cap & Net Worth: Ningbo Menovo Pharm Co Ltd (603538)
Ningbo Menovo Pharm Co Ltd market cap. Ningbo Menovo Pharm Co Ltd (SHG:603538) has a market capitalization of $1.01 Billion (CN¥6.89 Billion) as of October 30, 2026. Listed on the SHG stock exchange, this China-based company holds position #8582 globally and #1964 in its home market, demonstrating a -10.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ningbo Menovo Pharm Co Ltd's stock price CN¥20.28 by its total outstanding shares 339928188 (339.93 Million).
Ningbo Menovo Pharm Co Ltd Market Cap History (2017–2026)
Ningbo Menovo Pharm Co Ltd market cap history from 2017 to 2026. Data shows change from $753.01 Million to $1.01 Billion (-9.83% CAGR). Check Ningbo Menovo Pharm Co Ltd share price for real-time trading data and today's change.
Ningbo Menovo Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ningbo Menovo Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 603538 cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.64x
Ningbo Menovo Pharm Co Ltd's market cap is 0.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.36x
Ningbo Menovo Pharm Co Ltd's market cap is 9.36 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $753.01 Million | $605.32 Million | $44.68 Million | 1.24x | 16.85x |
| 2018 | $682.63 Million | $848.96 Million | $96.35 Million | 0.80x | 7.08x |
| 2019 | $864.52 Million | $1.18 Billion | $150.90 Million | 0.73x | 5.73x |
| 2020 | $1.30 Billion | $1.19 Billion | $155.96 Million | 1.09x | 8.35x |
| 2021 | $1.25 Billion | $1.26 Billion | $142.53 Million | 0.99x | 8.74x |
| 2022 | $1.27 Billion | $1.46 Billion | $338.86 Million | 0.87x | 3.75x |
| 2023 | $951.07 Million | $1.22 Billion | $11.59 Million | 0.78x | 82.09x |
| 2024 | $632.22 Million | $1.37 Billion | $66.81 Million | 0.46x | 9.46x |
| 2025 | $957.04 Million | $1.50 Billion | $102.23 Million | 0.64x | 9.36x |
Competitor Companies of 603538 by Market Capitalization
Companies near Ningbo Menovo Pharm Co Ltd in the global market cap rankings as of October 30, 2026. See 603538 net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Ningbo Menovo Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Ningbo Menovo Pharm Co Ltd (2017–2026)
Market capitalization of Ningbo Menovo Pharm Co Ltd from 2017 to today. Between 2017 and today, Ningbo Menovo Pharm Co Ltd's market cap moved from $753.01 Million to $ 1.01 Billion, with a yearly change of -9.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.01 Billion | +5.41% |
| 2025 | CN¥957.04 Million | +51.38% |
| 2024 | CN¥632.22 Million | -33.53% |
| 2023 | CN¥951.07 Million | -25.14% |
| 2022 | CN¥1.27 Billion | +1.96% |
| 2021 | CN¥1.25 Billion | -4.36% |
| 2020 | CN¥1.30 Billion | +50.71% |
| 2019 | CN¥864.52 Million | +26.65% |
| 2018 | CN¥682.63 Million | -9.35% |
| 2017 | CN¥753.01 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Ningbo Menovo Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.01 Billion USD |
| MoneyControl | $1.01 Billion USD |
| MarketWatch | $1.01 Billion USD |
| marketcap.company | $1.01 Billion USD |
| Reuters | $1.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more